Abstract: The invention relates to a microactuator arranged on a thermally insulating layer (2) and having a resistance layer (4) made from doped diamond, which is provided with an electrical supply and an electrical leakage (9).
Type:
Grant
Filed:
December 4, 2001
Date of Patent:
January 14, 2003
Assignee:
Merckle GmbH
Inventors:
Eberhard P. Hofer, Erhard Kohn, Christian Rembe, Stefan Aus Der Wiesche, Peter Gluche, Rudiger Leuner
Abstract: The invention relates to 4-heteroaryl-5-phenylimidazole derivatives having 2-arylalkylthio, 2-arylalkenylthio and 2-arylalkynylthio substitution, of the general formula I:
in which Ar is a phenyl radical, Het is a hetero aromatic radical, A is an alkylene chain, R1 is an alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamido or alkylcarbonyl group and R2 is an alkyl, hydroxyl, alkoxy, alkoxycarbonyl, sulfonamido, carboxyl, nitro or aminocarbonyl group or a halogen atom. n can be 1 or 2 and m is 0 to 2. The compounds according to the invention show antiinflammatory activity.
Type:
Grant
Filed:
May 11, 2001
Date of Patent:
August 13, 2002
Assignee:
Merckle GmbH
Inventors:
Stefan Laufer, Hans-Günter Striegel, Karola Neher
Abstract: The present invention relates to a process process for the preparation of the compound of the formula I
where the compound of the formula III
is reacted with oxalyl chloride and the product obtained is treated with hydrazine and an alkali metal hydroxide in the aqueous phase at elevated temperature, after treatment is complete a three-phase system is produced by addition of an ether and the compound of the formula I is obtained by acidifying the middle phase.
The invention moreover relates to a polymorph of the compound of the formula I.
Type:
Grant
Filed:
January 26, 2001
Date of Patent:
July 9, 2002
Assignee:
Merckle GmbH
Inventors:
Thomas Kammermeier, Stefan Laufer, Philipp Merckle, Hans-Guenter Striegel
Abstract: The invention provides novel antiinflammatory and analgesic agents of the formulae
The novel compounds have an improved inhibitory effect and/or less cytotoxicity in comparison with compounds known from the prior art. The compounds according to the invention are outstandingly suitable for preventing and/or treating disorders caused or partly caused by an increased activity of the enzyme phospholipase A2, such as, for example, inflammations, allergies, asthma, psoriasis and endotoxic shock.
Abstract: The present invention relates to heterocyclic compounds of the formula ##STR1## in which R.sup.1 -R.sup.7, B, a and X have the meanings recited in the specification. These compounds are usable in the treatment of diseases of the rheumatoid variety and for the prevention of allergically induced diseases.
Type:
Grant
Filed:
March 28, 1996
Date of Patent:
September 28, 1999
Assignee:
Merckle GmbH
Inventors:
Stefan Laufer, Hans Gunther Striegel, Gerd Dannhardt
Abstract: The present invention relates to heterocyclic compounds of the formula ##STR1## in which R.sup.1 -R.sup.7, B, a and X have the meanings recited in the specification. These compounds are usable in the treatment of diseases of the rheumatoid group and for the prevention of allergically induced diseases.
Type:
Grant
Filed:
March 28, 1997
Date of Patent:
August 24, 1999
Assignee:
Merckle GmbH
Inventors:
Stefan Laufer, Hans Gunther Striegel, Gerd Dannhardt
Abstract: The present invention relates to heterocyclic compounds with the formula ##STR1## in which R.sup.1 to R.sup.7, B, a, and X have the meanings indicated in the specification. These compounds can be used for the treatment of diseases of the rheumatic variety and for the prevention of allergically-induced diseases.
Type:
Grant
Filed:
March 28, 1997
Date of Patent:
August 17, 1999
Assignee:
Merckle GmbH
Inventors:
Stefan Laufer, Hans Gunther Striegel, Gerd Dannhardt
Abstract: The invention concerns substituted pyrrole compounds and their pharmaceutical applications. The compounds of the invention are potent inhibitors of lipoxygenase and cyclo-oxygenase and therefore are suitable to treat the set of rheumatic illnesses and to prevent allergically induced ailments. The compounds have the general formula: ##STR1## where R.sup.1 denotes a C.sub.1 -C.sub.12 alkyl group, R.sup.2 denotes a hydrogen atom or a C.sub.1 -C.sub.12 alkyl group, or R.sup.1 and R.sup.2 together with the carbon atom and the nitrogen atom to which they are bound form a ring of 5 to 8 links which may contain a sulfur heteroatom or a carbonyl group and may be substituted with one or two C.sub.1 -C.sub.4 alkyl groups,each time two of the residues R.sup.3, R.sup.4 and R.sup.5 independently from one another represent a hydrogen atom, a C.sub.5 -C.sub.8 cycloalkyl group, a C.sub.1 -C.sub.12 alkyl group or an aryl group which may be substituted by one or two residues selected from a halogen atom, a nitro-, a C.sub.1 -C.
Type:
Grant
Filed:
May 21, 1992
Date of Patent:
November 9, 1993
Assignees:
Merckle GmbH, G. Dannhardt
Inventors:
Gerd Dannhardt, Ludwig Steindl, Matthias Lehr
Abstract: By using a new method 2-(2-hydroxyethoxy)-ethanol ester is produced from flufenamic acid as a result of direct esterification with diol with an excess of 8-15 mol diol per mol flufenamic acid without concurrent removal of water.
Abstract: Novel diethylene glycol monoester of antirheumatically effective acids, e.g., lonazolac and diclofenac and others are disclosed which have inflammation inhibitory properties superior to the corresponding acid base forms. They may be produced through direct esterification without elimination of water and are suitable in the fight against diseases of the rheumatic complex.
Type:
Grant
Filed:
March 31, 1989
Date of Patent:
October 2, 1990
Assignee:
Merckle GmbH
Inventors:
Gunter Metz, Kurt Rauchle, Manfred Erdmann
Abstract: Disclosed are aqueous, stable, relatively concentrated solutions of diclofenac, which contain a mixture of propylene glycol and polyethylene glycol in defined quantitative proportions. The solutions preferably contain a local anesthetic such as lidocaine and a reducing agent as stabilizer.
Type:
Grant
Filed:
December 20, 1985
Date of Patent:
December 8, 1987
Assignee:
Merckle GmbH
Inventors:
Otto von Stetten, Pyare L. Seth, Franz Schmid, Kurt Rauchle
Abstract: The invention relates to the use of naproxen lysinate, ketoprofen lysinate and/or diclofenac lysinate in the form of an injectable solution in the treatment of inflammations and rheumatic disorders, and to injectable solutions containing the anti-inflammatory active compound naproxen, ketoprofen or diclofenac in the form of its lysinate.
Abstract: At least one barbiturate or one of its pharmaceutically acceptable salts is combined with cinnarizine or flunarizine or one of their pharmaceutically acceptable salts to provide a hypnotic requiring lower dosages of barbiturates to produce the same effect as the barbiturate alone.